Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2021-11-08 Declaration of Voting R…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Kommuniké från extra bolagsstämma i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'Kommuniké från extra bolagsstämma' (Communiqué from an Extraordinary General Meeting) for Alligator Bioscience AB. It details the specific decisions made during the meeting, including amendments to the articles of association and approval of a rights issue. Since it reports the official results and decisions of a shareholder meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2021-11-08 Swedish
Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB
Board/Management Information Classification · 1% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the 'Annual General Meeting (AGM) on May 5, 2022'. It details the composition, responsibilities, and submission deadlines for proposals related to the AGM. This content directly relates to the governance and preparatory materials for the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-11-03 English
Valberedning utsedd inför årsstämma 2022 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "Valberedning utsedd inför årsstämma 2022 i Alligator Bioscience AB" (Nomination Committee appointed ahead of the Annual General Meeting 2022 in Alligator Bioscience AB). It details the composition and mandate of the Nomination Committee, which is responsible for preparing proposals for the Annual General Meeting (AGM), such as board members and remuneration. This content directly relates to the preparatory work and governance surrounding the AGM. While it is an announcement, the subject matter is specifically about the AGM's preparatory body (the Nomination Committee), which aligns closely with AGM-related materials. Since the document is about the appointment of the committee responsible for proposing items for the AGM, the most fitting category is AGM Information (AGM-R), as it is material directly related to the upcoming Annual General Meeting.
2021-11-03 Swedish
Alligator ingår avtal om teckningsförbindelser med styrelseledamöter och ledande befattningshavare
Capital/Financing Update Classification · 1% confidence The document is a press release written in Swedish announcing that board members and senior management have formally committed to subscribing to their pro-rata shares in a rights issue ('Företrädesemissionen'). It discusses financing activities, capital structure changes (new share issue), and commitments from insiders (directors/management). This content strongly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions directors' commitments, the primary focus is the financing event itself, not just insider trading (DIRS) or a general management announcement (MANG). It is not a full report (10-K, IR) but an announcement related to capital raising.
2021-10-22 Swedish
Alligator enters into agreements on subscription commitments with board members and senior executives
Major Shareholding Notification Classification · 1% confidence The document is a press release announcing that board members and senior executives have formally undertaken subscription commitments for their pro rata share in an upcoming Rights Issue. This action relates directly to the company's capital structure and fundraising activities. While it discusses a future Prospectus, the document itself is an announcement regarding capital commitment related to a financing event. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full 10-K, an ER, or a general RNS, as it specifically details commitments for a capital raise.
2021-10-22 English
Earnings Release 2021
Earnings Release Classification · 1% confidence The document contains a CEO commentary, highlights of events for a specific period (July-September 2021), and detailed financial tables comparing Q3 2021 results with previous periods (Q3 2020, YTD 2021 vs YTD 2020). The structure, including key financial figures (Net sales, Operating result, Net result, Cash flow) presented for a quarterly period, strongly indicates a comprehensive report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains extensive financial statements and management discussion, nor is it the full Annual Report (10-K). 9M 2021
2021-10-21 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.